Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on September 1, 2016. The filing reports a material corporate governance event: the appointment of a new senior executive officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Mark J. Gergen as Senior Vice President and Chief Operating Officer, effective September 1, 2016. Mr. Gergen previously served as Executive Vice President and Chief Operating Officer at Mirati Therapeutics, Inc. (2013–2016) and held senior roles at Amylin Pharmaceutical, Inc. (2005–2012).
Management Commentary and Compensation
Management has outlined the following compensatory arrangements for Mr. Gergen:
- Base Salary: $435,000 annually.
- Bonus Target: 45% of his prorated base salary for 2016.
- Equity Grant: Stock options for 333,890 shares of common stock, subject to a standard four-year vesting schedule.
- Eligibility: Participation in the Company's executive officer incentive plans.
The filing states there are no family relationships between Mr. Gergen and other directors or officers, and he holds no material interest in transactions involving the Company.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 333,890 stock options granted to Mr. Gergen.
- Review the attached press release (Exhibit 99.1) for strategic context regarding the appointment.
- Confirm the impact of this appointment on the Company's existing executive compensation structure.